Discover open access scientific publications

A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients With Chronic Lymphocytic Leukemia (Cll) Who Are Intolerant to Prior BTK or Pi3k Delta Inhibitor Therapy